Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Stock Quote Today & Recent News Amylyx Pharmaceuticals Inc AMLX

Amylyx Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery and development of treatments for neurodegenerative diseases. The Company is focused on the development and commercialization of its product candidate, AMX0035 (sodium phenylbutyrate and taurursodiol, also known as ursodoxicoltaurine) for the treatment of amyotrophic lateral... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >

Current News (NDAQ:AMLX)

Lifshitz Law PLLC Announces Investigations of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX), Cassava Sciences, Inc. (NASDAQ:SAVA), GrafTech International Ltd. (NYSE:EAF), and Mobileye Global Inc. (NASDAQ:MBLY)

Accesswire 4 hours ago

Lifshitz Law PLLC Announces Investigations of Meta Platforms, Inc. (NASDAQ: META), Amplitude, Inc. (NASDAQ: AMPL), ON Semiconductor Corporation (NASDAQ: ON), and Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)

Accesswire 9 days ago

Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome

Business Wire April 10, 2024

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyx

Newsfile April 9, 2024

April 9, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against - AMLX

Accesswire April 9, 2024

AMLX DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Alerts Amylyx Pharmaceuticals (AMLX) Investors to Today's Lead Plaintiff Deadline in Securities Fraud Class Action

Accesswire April 9, 2024

Investors in Amylyx Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights - AMLX

Accesswire April 9, 2024

Levi & Korsinsky Notifies Shareholders of Amylyx Pharmaceuticals, Inc.(AMLX) of a Class Action Lawsuit and an Upcoming Deadline

Accesswire April 9, 2024

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Amylyx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Accesswire April 9, 2024

Opinion & Analysis (NDAQ:AMLX)

No current opinion is available.

Bullboard Posts (NDAQ:AMLX)

CAN AMX0035 BE A POTENTIAL GAME CHANGER IN ALS?

  $AMLX   Excited to share an article about Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) that is awaiting regulatory...
AviseAnalytics - March 16, 2022